Literature DB >> 31376032

Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.

Rebecca A Marsh1, Jennifer W Leiding2, Brent R Logan3, Linda M Griffith4, Danielle E Arnold5, Elie Haddad6, E Liana Falcone7, Ziyan Yin3, Kadam Patel3, Erin Arbuckle8, Jack J Bleesing1, Kathleen E Sullivan5, Jennifer Heimall5, Lauri M Burroughs9, Suzanne Skoda-Smith10, Shanmuganathan Chandrakasan11, Lolie C Yu12, Benjamin R Oshrine13, Geoffrey D E Cuvelier14, Monica S Thakar9, Karin Chen15, Pierre Teira16, Shalini Shenoy17, Rachel Phelan18, Lisa R Forbes19, Deepak Chellapandian20, Blachy J Dávila Saldaña21, Ami J Shah22, Katja G Weinacht23, Avni Joshi24, Farid Boulad25, Troy C Quigg26, Christopher C Dvorak27, Debi Grossman28, Troy Torgerson29, Pamela Graham28, Vinod Prasad30, Alan Knutsen31, Hey Chong32, Holly Miller33, M Teresa de la Morena34, Kenneth DeSantes35, Morton J Cowan27, Luigi D Notarangelo36, Donald B Kohn37, Elizabeth Stenger38, Sung-Yun Pai39, John M Routes40, Jennifer M Puck27, Neena Kapoor41, Michael A Pulsipher41, Harry L Malech28, Suhag Parikh42, Elizabeth M Kang43.   

Abstract

INTRODUCTION: Inflammatory bowel disease (IBD) affects approximately 1/3 of patients with chronic granulomatous disease (CGD). Comprehensive investigation of the effect of allogeneic hematopoietic cell transplantation (HCT) on CGD IBD and the impact of IBD on transplant outcomes is lacking.
METHODS: We collected data retrospectively from 145 patients with CGD who had received allogeneic HCT at 26 Primary Immune Deficiency Treatment Consortium (PIDTC) centers between January 1, 2005 and June 30, 2016.
RESULTS: Forty-nine CGD patients with IBD and 96 patients without IBD underwent allogeneic HCT. Eighty-nine percent of patients with IBD and 93% of patients without IBD engrafted (p = 0.476). Upper gastrointestinal acute GVHD occurred in 8.5% of patients with IBD and 3.5% of patients without IBD (p = 0.246). Lower gastrointestinal acute GVHD occurred in 10.6% of patients with IBD and 11.8% of patients without IBD (p = 0.845). The cumulative incidence of acute GVHD grades II-IV was 30% (CI 17-43%) in patients with IBD and 20% (CI 12-29%) in patients without IBD (p = 0.09). Five-year overall survival was equivalent for patients with and without IBD: 80% [CI 66-89%] and 83% [CI 72-90%], respectively (p = 0.689). All 33 surviving evaluable patients with a history of IBD experienced resolution of IBD by 2 years following allogeneic HCT.
CONCLUSIONS: In this cohort, allogeneic HCT was curative for CGD-associated IBD. IBD should not contraindicate HCT, as it does not lead to an increased risk of mortality. This study is registered at clinicaltrials.gov NCT02082353.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; chronic granulomatous disease; inflammatory bowel disease; primary immunodeficiency

Mesh:

Year:  2019        PMID: 31376032      PMCID: PMC6754755          DOI: 10.1007/s10875-019-00659-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

1.  Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom.

Authors:  Alexandra C Battersby; Helen Braggins; Mark S Pearce; Catherine M Cale; Siobhan O Burns; Scott Hackett; Stephen Hughes; Dawn Barge; David Goldblatt; Andrew R Gennery
Journal:  J Allergy Clin Immunol       Date:  2017-03-23       Impact factor: 10.793

2.  Diagnostic and Treatment Options for Severe IBD in Female X-CGD Carriers with Non-random X-inactivation.

Authors:  Fabian Hauck; Sibylle Koletzko; Christoph Walz; Horst von Bernuth; Anne Klenk; Irene Schmid; Bernd H Belohradsky; Christoph Klein; Philip Bufler; Michael H Albert
Journal:  J Crohns Colitis       Date:  2015-10-13       Impact factor: 9.071

3.  X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability.

Authors:  Beatriz E Marciano; Christa S Zerbe; E Liana Falcone; Li Ding; Suk See DeRavin; Janine Daub; Samantha Kreuzburg; Lynne Yockey; Sally Hunsberger; Ladan Foruraghi; Lisa A Barnhart; Kabir Matharu; Victoria Anderson; Dirk N Darnell; Cathleen Frein; Danielle L Fink; Karen P Lau; Debra A Long Priel; John I Gallin; Harry L Malech; Gulbu Uzel; Alexandra F Freeman; Douglas B Kuhns; Sergio D Rosenzweig; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2017-05-18       Impact factor: 10.793

4.  Residual NADPH oxidase and survival in chronic granulomatous disease.

Authors:  Douglas B Kuhns; W Gregory Alvord; Theo Heller; Jordan J Feld; Kristen M Pike; Beatriz E Marciano; Gulbu Uzel; Suk See DeRavin; Debra A Long Priel; Benjamin P Soule; Kol A Zarember; Harry L Malech; Steven M Holland; John I Gallin
Journal:  N Engl J Med       Date:  2010-12-30       Impact factor: 91.245

5.  Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease.

Authors:  Daniel J B Marks; Kana Miyagi; Farooq Z Rahman; Marco Novelli; Stuart L Bloom; Anthony W Segal
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

Review 6.  Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.

Authors:  Elena Soncini; Mary A Slatter; Laura B K R Jones; Stephen Hughes; Stephen Hodges; Terence J Flood; Dawn Barge; Gavin P Spickett; Graham H Jackson; Matthew P Collin; Mario Abinun; Andrew J Cant; Andrew R Gennery
Journal:  Br J Haematol       Date:  2009-02-16       Impact factor: 6.998

7.  Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry.

Authors:  L B K R Jones; P McGrogan; T J Flood; A R Gennery; L Morton; A Thrasher; D Goldblatt; L Parker; A J Cant
Journal:  Clin Exp Immunol       Date:  2008-05       Impact factor: 4.330

8.  A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.

Authors:  Pooja Khandelwal; Jacob J Bleesing; Stella M Davies; Rebecca A Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-16       Impact factor: 5.742

Review 9.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

10.  Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.

Authors:  Beatriz Morillo-Gutierrez; Rita Beier; Kanchan Rao; Lauri Burroughs; Ansgar Schulz; Anna-Maria Ewins; Brenda Gibson; Petr Sedlacek; Ladislav Krol; Brigitte Strahm; Irina Zaidman; Krzysztof Kalwak; Julie-An Talano; Ann Woolfrey; Chris Fraser; Isabelle Meyts; Ingo Müller; Jacek Wachowiak; Maria Ester Bernardo; Paul Veys; Karl-Walter Sykora; Andrew R Gennery; Mary Slatter
Journal:  Blood       Date:  2016-05-23       Impact factor: 22.113

View more
  8 in total

1.  Treatment of primary immunodeficiency with allogeneic transplant and gene therapy.

Authors:  Sung-Yun Pai
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Chronic Granulomatous Disease With Inflammatory Bowel Disease: Clinical Presentation, Treatment, and Outcomes From the USIDNET Registry.

Authors:  Brenna LaBere; Maria J Gutierrez; Hannah Wright; Elizabeth Garabedian; Hans D Ochs; Ramsay L Fuleihan; Elizabeth Secord; Rebecca Marsh; Kathleen E Sullivan; Charlotte Cunningham-Rundles; Luigi D Notarangelo; Karin Chen
Journal:  J Allergy Clin Immunol Pract       Date:  2022-01-14

Review 3.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

4.  Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation.

Authors:  Sharat Chandra; Shanmuganathan Chandrakasan; Pooja Khandelwal; Rebecca A Marsh; Blachy J Dávila Saldaña; Jack J Bleesing; Michael B Jordan; Ashish R Kumar; Michael S Grimley; Christa Krupski; Stella M Davies
Journal:  J Clin Immunol       Date:  2020-10-16       Impact factor: 8.317

Review 5.  Gene Therapies for Primary Immune Deficiencies.

Authors:  Lisa A Kohn; Donald B Kohn
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 6.  Advanced Understanding of Monogenic Inflammatory Bowel Disease.

Authors:  Ryusuke Nambu; Aleixo M Muise
Journal:  Front Pediatr       Date:  2021-01-22       Impact factor: 3.418

Review 7.  Understanding inborn errors of immunity: A lens into the pathophysiology of monogenic inflammatory bowel disease.

Authors:  Jodie Deborah Ouahed
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

Review 8.  Chronic Granulomatous Disease: a Comprehensive Review.

Authors:  Hsin-Hui Yu; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.